Skip to content

MDMA (3,4-Methylenedioxymethamphetamine)

An entactogen investigated primarily as an adjunct to psychotherapy for post-traumatic stress disorder.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, then ranked by relevance.

MDMA-assisted therapy (MDMA-AT) shows consistent, large-magnitude reductions in PTSD symptoms and functional impairment in two phase 3 RCTs, with effect sizes (d = 0.7–0.91) that are statistically significant and clinically meaningful. However, the evidence is limited to short-term follow-up (2 months post-treatment), and the durability of effects beyond one year is not established. Preclinical and observational studies also document MDMA's serotonergic neurotoxicity in animals and potential serotonin syndrome risk when combined with SSRIs, which are important safety caveats.

Confidence in the evidence

Moderate
  • Two phase 3 RCTs (n=90 and n=104) provide consistent, large effect sizes for PTSD symptom reduction, but both are industry-sponsored and have short follow-up.
  • The phase 2 pilot (n=12) showed non-significant CAPS scores (p=0.066) but significant self-reported improvement, indicating some inconsistency across measures.
  • Preclinical studies consistently show MDMA causes serotonergic axon terminal loss in rats, but human neurotoxicity evidence is limited to a single PET study (n=small) and indirect observational data.
  • No studies directly compare MDMA-AT to active psychotherapy or pharmacotherapy controls, limiting conclusions about relative efficacy.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. 2021
Supports

MDMA-assisted therapy produced a large and significant reduction in CAPS-5 scores compared to placebo (d=0.91, p<0.0001) and significantly improved functional impairment (d=0.43, p=0.0116).

RCT Sample size: 90

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. 2023
Supports

MDMA-AT significantly reduced CAPS-5 scores (d=0.7, p<0.001) and SDS functional impairment (d=0.4, p=0.03) compared to placebo with therapy.

RCT Sample size: 104

A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) 2012
Mixed

MDMA-assisted psychotherapy did not reach statistical significance on the clinician-rated CAPS (p=0.066) but showed significant improvement on the self-reported PDS (p=0.014), with further CAPS improvement at 1-year follow-up.

RCT Sample size: 12

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. 2018
Supports

MDMA-assisted psychotherapy reduced PTSD symptoms in a dose-response phase 2 trial in first responders.

RCT

The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. 2010
Supports

The first randomized controlled pilot study found MDMA-assisted psychotherapy to be safe and efficacious in treatment-resistant PTSD.

RCT

Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity 1988
Opposes

MDMA and MDA caused selective ablation of serotonergic axon terminals in rat forebrain, with fine 5-HT terminals being extremely vulnerable.

preclinical

3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. 1987
Opposes

Repeated MDMA administration caused 50-75% reductions in 5-HT uptake sites in rat brain regions, indicating long-lasting serotonergic neurotoxicity.

preclinical

Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings 1998
Opposes

PET imaging showed direct evidence of decreased 5-HT transporter binding in the brains of human MDMA users, suggesting serotonergic neurotoxicity.

observational

Human Pharmacology of MDMA 2004
Unclear

MDMA acts as a potent releaser/reuptake inhibitor of serotonin, dopamine, and norepinephrine, producing entactogen effects but also acute toxicity including serotonin syndrome.

review

Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin 2000
Unclear

MDMA releases norepinephrine more potently than dopamine or serotonin, and this NE release correlates with amphetamine-type subjective effects in humans.

preclinical

The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. 1992
Unclear

MDMA stimulates serotonin efflux via direct interaction with both plasma membrane and vesicular serotonin transporters.

preclinical

Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs 2006
Unclear

MDMA exhibited higher potency at SERT than at DAT, distinguishing it from amphetamine and methamphetamine.

preclinical

Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens 1986
Unclear

MDMA was identified as a member of a new therapeutic class called 'entactogens,' distinct from classic hallucinogens and amphetamines.

theoretical

Subjective Reports of the Effects of MDMA in a Clinical Setting 1986
Unclear

Subjective reports from a clinical setting described MDMA's effects as facilitating interpersonal closeness and emotional openness.

qualitative

Recreational MDMA use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug 1992
Mixed

Recreational users reported positive mood and intimacy, but tolerance developed to positive effects while negative effects increased with use; animal neurotoxicity data were noted as a concern.

observational Sample size: 100

Changes in trauma symptoms of discrimination after MDMA-assisted psychotherapy for posttraumatic stress disorder. 2026
Supports

MDMA-assisted therapy was associated with a 38% reduction in trauma symptoms of discrimination (d=1.28, p=0.046), though the sample was very small.

observational Sample size: 5

Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA 2026
Unclear

MDMA treatment was associated with DNA methylation changes in 346 genes, enriched for neuroplasticity and neuroimmune pathways.

observational Sample size: 16

A neurocognitive account of complex PTSD: self-modelling, affective dysregulation, and implications for MDMA-assisted and targeted psychotherapies. 2026
Unclear

A neurocognitive model proposes MDMA-assisted psychotherapy may modulate affective salience, interpersonal trust, and self-referential cognition in C-PTSD.

theoretical

α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in mice. 2026
Unclear

MDMA's noradrenergic effects via α2 receptors may oppose 5-HT2A-mediated behavioral effects, suggesting polypharmacology modulates its psychedelic-like actions.

preclinical

What are the risks of serotonin syndrome when using MDMA and SSRIs together? 2026
Opposes

Limited evidence suggests combined use of MDMA and SSRIs may increase the risk of serotonin syndrome.

review

EFICÁCIA COMPARATIVA DE PSICODÉLICOS (PSILOCIBINA E MDMA) NO TRATAMENTO DE TRANSTORNO DE ESTRESSE PÓS-TRAUMÁTICO E DEPRESSÃO RESISTENTE AO TRATAMENTO: REVISÃO SISTEMÁTICA 2026
Supports

A systematic review of 3 MDMA trials in PTSD reported 67-71% of participants no longer met PTSD diagnostic criteria after MDMA-AT.

review

Open MDMA: An Evidence-Based Synthesis, Theory, and Manual for MDMA Therapy Based on Memory Reconsolidation, Complex Systems, and the Defense Cascade 2026
Unclear

A theoretical manual proposes MDMA therapy works through memory reconsolidation and predictive processing, but is not an empirical study.

theoretical

Sexual identity as a moderator of associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes: An exploratory analysis of a nationally representative sample using NSDUH 2015–2019 2026
Unclear

Sexual identity moderated associations between lifetime MDMA use and mental health outcomes, but direction was not specified in the abstract.

observational

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants. 2026
Unclear

MDMA (125 mg) produced the highest cardiovascular stimulation among the drugs tested and increased plasma oxytocin, but did not induce 'bad drug effects' or anxiety unlike psilocybin.

RCT Sample size: 24

Dermatological manifestations associated with chemsex 2026
Opposes

MDMA use in chemsex is associated with oral mucositis and painful aphthous-like ulcers due to bruxism and xerostomia.

review

Points of agreement

  • Two phase 3 RCTs consistently show MDMA-AT significantly reduces PTSD symptoms and functional impairment compared to placebo with therapy.
  • Preclinical studies consistently demonstrate MDMA causes serotonergic axon terminal loss and reductions in 5-HT markers in rat brain.
  • Multiple studies describe MDMA's mechanism as a monoamine releaser with highest potency at serotonin transporters, distinguishing it from classic amphetamines.
  • Subjective and clinical reports converge on MDMA producing feelings of closeness, empathy, and emotional openness.

Conflicts

  • The phase 2 pilot (n=12) found non-significant clinician-rated CAPS scores (p=0.066) while the larger phase 3 trials found highly significant effects, possibly due to sample size.
  • Recreational user reports describe tolerance and increasing negative effects with frequent use, whereas clinical trials report good safety profiles with supervised administration.
  • Preclinical neurotoxicity findings in rats contrast with the absence of reported long-term cognitive decline in clinical trial participants, though human neurotoxicity data are limited.

Gaps

  • Durability of MDMA-AT effects beyond 1-2 years is not established.
  • No direct comparisons of MDMA-AT to first-line PTSD treatments (e.g., prolonged exposure, cognitive processing therapy) exist.
  • Human neurotoxicity evidence is limited to one small PET study and indirect observational data; long-term cognitive effects in clinical populations are unstudied.
  • Safety and efficacy in diverse populations (e.g., by race/ethnicity, sexual orientation) are only beginning to be explored.
  • Optimal dosing, number of sessions, and integration protocols are not systematically compared.
  • Drug-drug interaction risks (e.g., with SSRIs, other medications) are poorly characterized in clinical populations.
Browse these studies in the library
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is MDMA, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when MDMA or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: June 2026 →

2,227 articles · 607 from the last two years · 8,254,111 participants across 771 studies reporting sample size

Common study designs

review 471 experimental study 171 observational cohort 103 cross-sectional survey 83 theoretical or philosophical paper 145

Research

Synthesize the evidence → Search all →

Effectiveness and Experiences of Psychedelic-Based Interventions for the Treatment of Alcohol Use Disorder: A Mixed Methods Systematic Review

Baneet Gill

A mixed-methods systematic review of eight studies (four quantitative, four qualitative) examined the effectiveness and experiences of using psychedelics to treat alcohol use disorder (AUD). Quantitative studies reported an overall increase in abstinence and a decrease in drinking days after treatment, while qualitative studies reported mostly positive experiences. However, the included studies were rated mostly 'poor' or 'moderate' quality, so results should be interpreted with caution. The small number of recent studies, small sample sizes, and heterogeneity of studies limit the strength of conclusions, highlighting the need for further research.

DOI: 10.31237/osf.io/tqa8j_v1

Evidence-Based Medicine is inadequate to develop evidence-based psychedelic therapies.

Eduardo Ekman Schenberg preprint

Between April and October 2024, expert bodies in the US and the Netherlands reached opposite conclusions on MDMA for PTSD. The FDA rejected Lykos Therapeutics' New Drug Application despite prior breakthrough therapy status, while the Dutch State Commission recommended making the treatment available as soon as possible. These contrasting decisions highlight epistemic differences in evidence assessment: the FDA's approach aligned with traditional Evidence-Based Medicine (EBM), whereas the Dutch approach resembled the newer EBM+ framework. Drawing on historical fatal examples and recent evidence-assessment debates (e.g., masking during COVID-19), the authors argue that shifting to EBM+ is essential for reliable assessments of psychedelic therapies.

DOI: 10.31234/osf.io/rzdpm

Binaries, Multitudes, and Beyond: A Client-Authored Case Study in Psychedelic-Assisted Therapy, Artificial Intelligence, and Narrative Agency

Mark A. Michaels

A client who is also the author documents a 10-week course of collaborative therapy that integrates EMDR, ketamine, MDMA, psilocybin, creative expression, and AI-assisted reflection and writing. Drawing on affect theory, mentalization, earned secure attachment, and Dabrowski's theory of positive disintegration, the paper analyzes how recognition of core affects, rupture-and-repair processes, and the reclamation of narrative agency contributed to rapid, positive change. Psychoeducation supported a deep exploration of these concepts. The case critiques traditional psychoanalytic framings, diagnostic overreach, and hierarchical therapeutic structures, arguing for a model emphasizing collaboration, agency, and narrative coherence. It also highlights the potential and limitations of generative AI as an adjunct in psychotherapy and narrative self-reclamation.

DOI: 10.2139/ssrn.6317678

Malpractice without a Baseline: Tort Liability and the Structural Paradoxes of Psychedelic-assisted Therapy

Michael Palmieri

Psychedelic-assisted therapy is moving toward clinical legitimacy in the United States, with the FDA granting Breakthrough Therapy designations to psilocybin and MDMA and major research investments underway. However, the legal framework for malpractice liability in this field remains undeveloped. The article identifies three structural challenges: the standard of care is unclear because the profession lacks settled credentialing and practice standards; causation analysis is complicated when treatment intentionally alters a patient's evaluative framework; and damages calculations face a paradox when identity transformation may later be viewed as beneficial. The article argues these are permanent structural features, not transitional problems, and proposes doctrinal adaptations such as prospective consent architectures and tiered standard-of-care frameworks.

DOI: 10.2139/ssrn.6383498

Consent Without Continuity: Psychedelic-Assisted Therapy and the Structural Failure of Informed Consent Doctrine

Michael Palmieri

American informed consent law assumes that a patient's values and decision-making framework remain stable from the moment they authorize a treatment through the period when they experience its effects. Psychedelic-assisted therapy, using compounds like psilocybin and MDMA, deliberately alters patients' values, self-concept, and evaluative frameworks as a therapeutic goal, breaking that continuity. This article argues that when a treatment transforms the cognitive architecture through which risk is assessed, standard consent doctrines—materiality, causation, and capacity—fail. The author proposes a dynamic consent model with pre-session identity-impact disclosures, staged reaffirmation checkpoints, integration-phase consent validation, and longitudinal documentation reforms.

DOI: 10.2139/ssrn.6383378

MDMA impairs response to water intake in healthy volunteers

bioRxiv (Cold Spring Harbor Laboratory) Matthew J. Baggott, Kathleen J. Garrison 1 citation preprint

MDMA (ecstasy) use can cause dangerously low blood sodium levels (hyponatremia), especially when people drink too much water. In two double-blind, placebo-controlled studies, healthy volunteers who took MDMA did not show increased levels of the hormone that normally regulates water balance (ADH or copeptin), but their blood sodium dropped more than with placebo when they drank standardized amounts of water. Women tended to have lower baseline sodium, but this did not significantly interact with MDMA. The findings indicate that consuming hypotonic fluids during MDMA use poses a significant risk of hyponatremia, which should be anticipated and managed in clinical and recreational settings.

DOI: 10.1101/021113

The Birth of the Psychedelic Industry: Capitalizing on the Psychedelic Renaissance

Minsu Yoo, Sofia Sakopoulos

The commercialization of psychedelics like psilocybin, LSD, and MDMA for mental health treatment blurs the line between impartial science and profit-driven industry. Based on in-depth interviews with stakeholders, the study reveals how venture capitalists not only fund research but also provide regulatory and industry knowledge, creating ethical dilemmas for scientists. Researchers' reluctance to disclose personal psychedelic experiences during interviews signals a shift from an illegality paradigm to one of intellectual property. The findings suggest that ethical dynamics in scientific practice must be reconsidered, particularly how public and private funders shape researchers' priorities.

DOI: 10.22541/au.172496618.87990987/v1

Psychedelics Use and the Risk of Reduced Formal Mental Health Care

Research Square Sean Viña

People who use psychedelics are less likely to seek formal mental health care, including medication and outpatient treatment, even when experiencing high psychological distress. Analyzing data from over 458,000 participants in a national US survey between 2010 and 2018, the study found that as distress levels increase, psychedelic users become even less inclined to use formal care compared to non-users. This suggests a heightened risk of self-medication as psychedelics become more culturally and legally accepted.

DOI: 10.21203/rs.3.rs-4378944/v1

MDMA-Based Psychotherapy in Treatment-Resistant Post-traumatic Stress Disorder (PTSD): A Brief Overview of Current Evidence

Preprints.org Kainat Riaz, Sejal Suneel, Mohammad Hamza Bin Abdul Malik et al. 1 citation preprint

Half of patients with post-traumatic stress disorder (PTSD) do not respond to standard pharmacotherapy or psychotherapy. A review of six phase II randomized controlled trials indicates that MDMA-assisted psychotherapy can reduce PTSD symptoms, even in treatment-resistant cases, by increasing neurohormones such as dopamine, serotonin, norepinephrine, and oxytocin and by modulating brain regions involved in fear and anxiety. The FDA has granted MDMA-assisted psychotherapy a "Breakthrough Therapy" designation. Further research is needed to determine whether the benefits outweigh the risks and whether this approach can be integrated into existing treatment options.

DOI: 10.20944/preprints202308.1847.v1

MDMA Assisted Psychotherapy Decreases PTSD Symptoms, Dissociation, Functional Disability, and Depression: A Systematic Review and Meta-Analysis

medRxiv W. M. Green, S.b. Raut, F.l.j. James et al. 4 citations preprint

MDMA-assisted psychotherapy improves dissociation, depression, and functional impairment in people with post-traumatic stress disorder (PTSD), but does not improve sleep quality. A systematic review and meta-analysis of randomized controlled trials found that the therapy reduces core PTSD symptoms and enhances quality of life. The evidence is limited by small sample sizes in available trials, but supports further development of MDMA-assisted psychotherapy for PTSD.

DOI: 10.1101/2023.08.17.23293955

Clinical trials

All MDMA trials →